For full functionality of this website it is necessary to enable JavaScript. Here are the instructions how to enable JavaScript in your web browser

Session Details

MSCs in the Clinic: A Post-Mortem Examination
Wednesday, May 29, 2024 09:15 AM - 10:15 AM  
Room 217-219
Clinic & Therapeutic Development
Roundtable
Organized by: ISCT Clinical Translation Committee & ISCT Asia Regional Executive Committee

Moderators
  • ​Jaap Jan Boelens, MD, PhD, Memorial Sloan Kettering Cancer Center, United States
  • Pawan Kumar Gupta, MD, DNB, PhD, MNAMS, Stempeutics Research Pvt. Ltd., India
Panelists
  • Jacques Galipeau, MD, FRCP(C), University of Wisconsin in Madison, United States
  • Steve Oh, B.Sc, Eng, PhD, Independent, Singapore
  • Iskra Pusic, MD, MSCI, Washington University School of Medicine, United States
The failure to gain regulatory approvals in spite of promising pre-clinical data holds lessons for the field. Understand how clinical trial heterogeneity and commercial manufacturing in the MSC space can inform future CGT development.

Key Learning Objectives
1) Harmonization / standardization manufacturing for same/similar product may help to increases success to commercialization (through clinical trial phases).
2) Hamonized / standardized clinical trial design will help to better / easier interpretation results and helps with journey to commercialization
Jaap Jan Boelens
Chief Transplantation and Cellular Therapies
 Memorial Sloan Kettering Cancer Center
 Co-moderator
Pawan Gupta
President - Medical & Regulatory Affairs
 Stempeutics Research
 Co-moderator
Jacques Galipeau
Professor and Associate Dean
 University of Wisconsin-Madison
 Panelist
Steve Oh
Chief Scientific Advisor
 CellVec Pte
 Panelist
Iskra Pusic
Associate Professor
 Washington University School of Medicine
 Panelist